Amarin Corp Plcuk (AMRN) Return on Capital Employed (2011 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Return on Capital Employed of 0.75% for Q1 2026, up 367.0% YoY from 0.16% in Q1 2025, and up 60.81% sequentially from 1.91% in Q4 2025.
Amarin Corp Plcuk (AMRN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Return on Capital Employed across 16 years of filings, most recently posting 0.75% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 367.0% year-over-year to 0.75%; the TTM figure through Mar 2026 stood at 0.75% (up 367.0% YoY), while the FY2025 annual figure was 1.86%, up 147.0% from the prior year.
- Return on Capital Employed grew to 0.75% in Q1 2026, from 1.91% in the prior quarter.
- Over the last five years, Return on Capital Employed for AMRN reached as high as 2.44% in Q2 2024 and fell as low as 16.6% in Q4 2022.
- The 5-year median for Return on Capital Employed is 4.42% (2025), against an average of 6.44%.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 1701 bps — and 2023, when it soared 1427 bps.
- A 5-year view of Return on Capital Employed shows it stood at 16.6% in 2022, then jumped by 86 bps to 2.33% in 2023, then plunged by 54 bps to 3.59% in 2024, then soared by 47 bps to 1.91% in 2025, then surged by 61 bps to 0.75% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 0.75%, 1.91%, and 4.94% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -0.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75% |
| Dec 31, 2025 | -1.91% |
| Sep 30, 2025 | -4.94% |
| Jun 30, 2025 | -7.95% |
| Mar 31, 2025 | -4.42% |
| Dec 31, 2024 | -3.59% |
| Sep 30, 2024 | 1.75% |
| Jun 30, 2024 | 2.44% |
| Mar 31, 2024 | -1.65% |
| Dec 31, 2023 | -2.33% |
| Sep 30, 2023 | -12.41% |
| Jun 30, 2023 | -9.51% |
| Mar 31, 2023 | -15.09% |
| Dec 31, 2022 | -16.60% |
| Sep 30, 2022 | -13.44% |
| Jun 30, 2022 | -15.65% |
| Mar 31, 2022 | -3.35% |
| Dec 31, 2021 | 0.41% |
| Sep 30, 2021 | 0.23% |
| Jun 30, 2021 | 1.18% |